-
The FDA approved a drug that slowed the growth of Alzheimer’s.
US’ Food and Drug Administration is expected to decide this week whether to give accelerated approval to lecanemab, an experimental Alzheimer’s drug, according to Biogen and Eisai. Lecanemab has been tested in a phase III clinical trial to see if it would stop brain shrinkage in Alzheimer’s patients. Earlier, three people had died after receiving…
-
The new report shared details about death that may be linked to the Alzheimer’s drug.
The Alzheimer’s Association has said it hopes the Centers for Medicare and Medicaid Services “will move quickly” to cover lecanemab for Alzheimer’s patients. “It will take clinicians some time to be available to parse out how this drug may or may not be effective in their own individual patients,” an expert said. The Alzheimer’s Association…
-
The study puts a leading theory to the ultimate test.
Alzheimer’s Association has asked the Centers for Medicare & Medicaid Services (CMS) to provide full and unrestricted coverage of FDA-approved Alzheimer’s treatments. This comes after lecanemab, a drug that removes amyloid from brain, was rejected as a treatment for Alzheimer’s. The Alzheimer’s Association said there are more than 300 Alzheimer’s treatments in clinical trials.